Abstract
Randomized controlled clinical trials are felt by the medical community to provide the best evidence. Participation in trials involves the possibility of obtaining benefits but also of suffering some risks. Those risks are often considered unacceptable for children but if clinical trials are not conducted in children, clinicians are forced to extrapolate study data from adults. In 1968 H. Shirkey termed children “therapeutic orphans” because of the lack of adequately tested and labeled drugs available in appropriate formulations. Research involving children entails specific difficulties as the need to study children of different ages, the small number of children affected by certain diseases or ethical issues. This paper considers aspects of pediatric clinical pharmacology and childrens responses to drugs. It also reviews some of the current situations in pediatric clinical trials, covering aspects such as: the benefits and risks of trial participation; the specificity of pediatric trial design; the ethical issues such as consent; the use of placebo or the participation of healthy children; and the current legal situation in Europe and in the USA.
Keywords: randomized controlled trials, Ethical issues, Institutional Review Boards (IRB), Pediatric Research Equity Act (PREA), FDAMA, Pediatric Clinical Research
Reviews on Recent Clinical Trials
Title: Clinical Trials in Children
Volume: 1 Issue: 3
Author(s): F. J. Morales-Olivas and C. Morales-Carpi
Affiliation:
Keywords: randomized controlled trials, Ethical issues, Institutional Review Boards (IRB), Pediatric Research Equity Act (PREA), FDAMA, Pediatric Clinical Research
Abstract: Randomized controlled clinical trials are felt by the medical community to provide the best evidence. Participation in trials involves the possibility of obtaining benefits but also of suffering some risks. Those risks are often considered unacceptable for children but if clinical trials are not conducted in children, clinicians are forced to extrapolate study data from adults. In 1968 H. Shirkey termed children “therapeutic orphans” because of the lack of adequately tested and labeled drugs available in appropriate formulations. Research involving children entails specific difficulties as the need to study children of different ages, the small number of children affected by certain diseases or ethical issues. This paper considers aspects of pediatric clinical pharmacology and childrens responses to drugs. It also reviews some of the current situations in pediatric clinical trials, covering aspects such as: the benefits and risks of trial participation; the specificity of pediatric trial design; the ethical issues such as consent; the use of placebo or the participation of healthy children; and the current legal situation in Europe and in the USA.
Export Options
About this article
Cite this article as:
Morales-Olivas J. F. and Morales-Carpi C., Clinical Trials in Children, Reviews on Recent Clinical Trials 2006; 1 (3) . https://dx.doi.org/10.2174/157488706778250087
DOI https://dx.doi.org/10.2174/157488706778250087 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of ncRNAs in Development, Diagnosis and Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Quassinoids: From Traditional Drugs to New Cancer Therapeutics
Current Medicinal Chemistry Identification of Two Novel Mutations in the <i>ATM</i> Gene from Patients with Ataxia-Telangiectasia by Whole Exome Sequencing
Current Genomics The Effects of Caffeine on the Cholinergic System
Mini-Reviews in Medicinal Chemistry Orthotopic Liver Transplantation in Non-Alcoholic Fatty Liver Disease Patients
Reviews on Recent Clinical Trials Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Biologic Drugs in Crohn's Disease and Ulcerative Colitis: Safety Profile
Current Drug Safety Immunomodulatory Effects of Medicinal Plants used for Vitiligo in Traditional Persian Medicine
Current Drug Discovery Technologies Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials MDM2 Inhibitors for Pancreatic Cancer Therapy
Mini-Reviews in Medicinal Chemistry Therapy Stratifications and Novel Approach in Pursuit of Aids Related Kaposi’s Sarcoma Management- A paradigm for Non Invasiveness
Current Drug Delivery Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry The Role of Diabetes Mellitus in Diseases of the Gallbladder and Biliary Tract
Current Diabetes Reviews Computational Drug Repositioning: A Lateral Approach to Traditional Drug Discovery?
Current Topics in Medicinal Chemistry Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry ES-MDA: Enhanced Similarity-based MiRNA-Disease Association
Current Protein & Peptide Science Effect of Low Dose Oral Vitamin-D and Calcium Replacement in HIV Patients
Recent Patents on Anti-Infective Drug Discovery Intraorganellar Acidification by V-ATPases: A Target in Cell Proliferation and Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies
Current Medicinal Chemistry